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Atrial fibrillation (AF) is the most common 
sustained heart rhythm disturbance (arrhythmia).2 
People with AF are three to five times more likely 
to suffer a devastating, debilitating, disabling 
and often fatal stroke than people without AF. 
Yet it is widely under‑recognised by the general 
public and policymakers.
AF‑related strokes cause unacceptably high levels 
of death and disability, and the scale of the problem 
across Europe is increasing as our populations age. 
By 2035 the number of strokes is projected to rise 
by 34%, to over 800,000 events.3 At the same time, 
the number of people with AF is increasing and, 
by 2060, it is estimated that nearly 18 million adults 
over the age of 55 will have AF.6 
We need to act now to prevent AF-related stroke.
Preventing stroke offers policymakers the potential to lower the cost  
of stroke care,3 contributing to more sustainable healthcare systems.
People face significant inequalities and unmet needs  
in AF-related stroke.
Consistent gaps and inequalities persist both in terms of rate of detection, and access and uptake 
of first‑line therapies and ongoing care for the prevention of AF‑related stroke. This White Paper 
highlights these inequalities and unmet needs and offers solutions to enable stakeholders 
at all levels to address this serious public health issue: 
With early detection, access to appropriate therapies and ongoing care and support, many 
AF‑related strokes can be prevented. Appropriate stroke‑prevention therapies have been shown 
to save lives and prevent disability in people with AF.1 They also reduce AF‑related hospital 
admissions, length of stay, outpatient visits7 8 and healthcare costs.9‑12
Recommendation 1: Build awareness and understanding of AF. Public awareness of AF 
as a cause of stroke is worryingly low and comes at a high price. We need population‑wide 
information campaigns with simple, targeted messages to address this. This should 
cover AF as a common cardiac condition, the link between heart conditions such as AF 
and stroke, and the importance of effective therapy in dramatically reducing stroke 
risk in people with AF. People diagnosed with AF should receive therapeutic education 
to build their knowledge of the condition and be involved in shared decision‑making 
with healthcare professionals.
This call to action is endorsed by: Professor John Camm; Sotiris Antoniou; Professor Anita Arsovska; 
Professor Valeria Caso; Dr Wolfram Doehner; Jean‑Luc Eiselé; Dr Johan Engdahl; Sue Koob; 
Trudie Lobban MBE; Professor Lis Neubeck; Professor Marten Rosenqvist; Dr Geert Vanhooren.
We therefore call on central governments to express a formal strategy 
or position on AF-related stroke. 
AF‑related stroke is a clear challenge to the future sustainability of healthcare systems 
and demands high‑level attention in every nation in Europe. This should align to the 
Action Plan for Stroke in Europe 2018–2030 and should include, at a minimum:
 ● an assessment of the current human and economic burden of AF as a cause of stroke
 ● an estimate of undiagnosed AF in the general population; and, for those with a diagnosis, 
an estimate of the current access to and uptake of first‑line therapy to prevent 
AF‑related stroke
 ● an assessment of systemic and structural strengths and weaknesses to explain 
current performance
 ● future projections of AF prevalence and their implications for the burden of stroke, 
with scenario modelling for guideline‑based efforts to reduce AF‑related stroke
 ● clear and measurable targets to prevent AF‑related stroke, and the identification 
of best‑value investments to achieve them
 ● adequate resources to ensure key actions can be implemented effectively.
Call to action
Recommendation 4: Ensure policy leadership to drive equitable access to best 
practice. We must ensure local and national policies are in place to tackle the structural 
barriers behind persistent inequalities in the detection of AF and access to first‑line 
therapies for AF‑related stroke. To achieve this, we must also raise awareness and 
understanding of AF among decision‑makers at all levels of the health system including 
administrators, managers and payers. 
Recommendation 3: Increase knowledge and skills of healthcare professionals. 
Awareness of AF as a stroke risk factor and effective knowledge of first‑line therapies 
for stroke prevention in AF are often inadequate outside of specialist cardiology settings. 
A wider range of healthcare professionals (e.g. GPs) must therefore be ready to play 
a key role in identifying AF and overseeing AF‑related stroke prevention. To help achieve 
this, we must develop tailored guidelines for non‑specialists, such as GPs, internists 
and nurses, and embed simple practices in everyday care.
Recommendation 2: Increase opportunistic detection of AF among high-risk 
groups. Too many cases of AF are undetected, and all too often AF is diagnosed too late, 
for example following a stroke. Pulse rhythm checks are recommended by European 
Society of Cardiology guidelines as a quick, affordable and proven method to test for 
AF when followed by an electrocardiogram for confirmation. Pulse rhythm checks can 
be performed opportunistically (e.g. during a routine health check), as well as in almost 
any community or social setting. Yet is it rare for them to be recommended by national 
guidelines, and adoption in everyday practice is highly variable. 
€38
A quarter of  
middle-aged adults 
will develop AF 
in their lifetime1
Stroke costs an 
estimated €38 billion 
across EU countries 
each year4 – and 
AF-related strokes 
are more expensive 
to manage than 
non-AF-related 
strokes.5  
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This White Paper sets out a clear call to action, highlighting areas where gaps exist 
and the changes that we need to put in place to address them. There are four key areas 
where action is required:
This report will consider the current situation in each of these areas, and recommend 
actions for advocates, healthcare professionals and decision‑makers to improve outcomes 
in the management of AF and prevention of AF‑related stroke.
About this White Paper:  
Why AF, and why now
Supporting patient education 1
Adapting clinical practice to enhance AF detection2
Strengthening clinical and professional training in AF3
Promoting awareness and accountability among decision-makers 
for effective AF-related stroke policies4
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Gaining a deeper understanding of 
inequalities in access to AF detection, 
care and management presents a significant 
opportunity to reduce the burden of 
AF-related stroke in Europe. As such, 
an evidence‑based consensus on the current 
state of play, leading implementation models, 
and key system barriers and opportunities 
faced by decision‑makers as they seek to drive 
improvements into mainstream healthcare 
is vital. 
With this aim in mind, Bristol‑Myers Squibb 
(BMS) and Pfizer (the BMS–Pfizer Alliance) 
commissioned a programme of work starting 
in 2017 with a literature review to provide 
greater insight into the inequalities in AF 
detection and stroke‑prevention therapies. 
This was followed by two expert meetings 
where leading figures working in AF and stroke 
were convened to better understand these 
inequalities, the underlying system and policy 
drivers responsible for them, and the possible 
actions that could be taken to address them. 
The Health Policy Partnership has been working 
with the BMS–Pfizer Alliance to coordinate 
research and drafting of the White Paper 
under the guidance of expert contributors.
This White Paper is the culmination of a 
consultative and consensus-driven process. 
It begins by placing AF and AF‑related stroke 
within the policy context, then focuses on four 
areas that are recognised by experts as critical 
to driving meaningful change for patients. 
In each of these areas, recommendations 
are made for how AF can be prioritised to 
improve outcomes and maximise benefits for 
both patients and the wider healthcare system.
This White Paper arrives at a critical 
moment for strategic health policymaking. 
Non‑communicable diseases (NCDs) are 
currently a major focus at the European level, 
with increasing attention being given to stroke. 
Recent developments include a European 
Union Joint Action on chronic diseases13 and 
a World Health Organization (WHO) European 
Region action plan for NCDs.14 This has created 
an opportunity to advance AF‑related stroke 
prevention at all levels. However, AF – and the 
link between AF and stroke – has so far been 
absent from these European‑level discussions. 
Stroke is a major contributor 
to non-communicable diseases.
Europe’s healthcare systems are under 
increasing pressure from ageing populations 
and a rise in non-communicable diseases 
(NCDs). Data suggest the number of people 
over the age of 65 is expected to rise from 
around 97 million in 2015 to more than 
125 million by 2030.23‑25 
Stroke is an important contributor to the 
NCD burden. In 2013, stroke was responsible 
for 433,000 deaths in Europe (9% of all deaths), 
and was the cause of a significant proportion 
of disability.26
The number of strokes across Europe – 
and the number of people living with the 
long-term effects of stroke – is predicted 
to rise. Stroke Alliance for Europe (SAFE) 
estimates that between 2015 and 2035, 
the number of new strokes will increase 
by 34%.3
There has been a shift 
in understanding of AF 
as a cause of strokes and 
in therapies to address risk.
The medical understanding of the risks 
associated with AF is a relatively recent 
development. As recently as the 1970s, 
AF was thought to be a benign condition, 
and it was not until the 1980s that attempts 
were made to fully understand the association 
between AF and stroke.22 
Over the past decade, there has been 
a rapid development of evidence regarding 
the role of therapies to prevent AF-related 
stroke. This is reflected in frequent updates 
in European Society of Cardiology (ESC) 
guidelines for the management of AF. 
The most recent edition, published in 2016, 
provides an update on AF‑related stroke 
prevention in the era of non‑vitamin K 
antagonist oral anticoagulant (NOAC) therapy; 
it recommends NOACs as a first‑line therapy 
for people with AF who are at a medium 
or high risk of stroke, and puts greater 
emphasis on the early detection of AF before 
an AF‑related stroke occurs.1 
AF is a major risk factor for stroke 
AF is a heart rhythm disorder that is an 
important risk factor for stroke,1 being 
associated with at least one in every five 
strokes2 (see Box 1). AF‑related strokes 
have also been found to have twice the 
mortality rate,5 cause more severe symptoms,15 
have a higher chance of recurrence,16 lead to 
longer hospital stays15 and lead to more 
permanent disability than non‑AF related 
strokes.15 17 Evidence is also accumulating 
that AF increases the risk for dementia.18 
Effective therapies reduce the risk of 
AF‑related stroke. There are, however, 
significant inequalities both in their use 
and in the successful detection of AF.19 
Introduction:  
What AF is, and why it matters
One in four middle-aged adults in Europe 
will develop AF in their lifetime.1 
What is AF, why does it occur,  
and how does it cause strokes?
 ● AF is the most common sustained heart rhythm disturbance (arrhythmia).2 AF occurs 
when abnormal electrical impulses take place in the upper chambers of the heart (atria), 
resulting in a highly irregular pulse rhythm.20 
 ● While the cause of AF is not fully understood, it is more common in older people and 
in people with other conditions including high blood pressure (hypertension), coronary 
artery disease, obesity, diabetes, chronic kidney disease or heart failure, which is the 
most common cause of death and hospital readmission among patients with AF.21
 ● By disrupting blood flow through the heart, AF increases the risk of blood clots forming,20 
making people with AF three to five times3 more likely to suffer a devastating, debilitating 
and often fatal stroke than people without AF.5 
Box 1
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What is the issue?
AF patients have been found to have gaps 
in knowledge of their condition, impacting 
both their health and their experience 
of care.  
This is, in part, a reflection of low levels 
of awareness and knowledge of AF across 
society more broadly.27 Some key areas where 
knowledge gaps exist include understanding 
of AF and the increased risk of stroke that AF 
brings (see Box 2). This lack of understanding 
is likely to be important in explaining low 
persistence with anticoagulants.28 
Why is this happening?
Gaps in access to helpful 
information exist in some 
countries. 
There are compelling models which provide 
information and support, including online 
tools, patient discussion forums and helplines 
for AF patients through patient advocacy 
groups and foundations in some countries.30‑32 
However, these resources and activities are not 
consistently available across Europe. 
Healthcare professionals often 
underuse educational tools.
A range of educational materials has been 
developed by patient organisations and 
professional societies. However, healthcare 
professionals often do not pass these on to 
patients, creating significant information gaps. 
For example:
 ● A recent study by the ESC found 
that, when discussing therapies with 
patients, only one third of clinicians used 
informational brochures and even fewer 
referred patients to educational websites.33
 ● In another study, only an average 14% of AF 
patients reported being informed of the 
potential side effects of their medication.34
Messages about AF and the risk 
of AF-related stroke may be 
difficult for patients to digest 
– particularly if they are being 
treated for multiple chronic 
conditions or if they are only 
diagnosed after they have had 
a stroke.
Many patients with AF have multiple chronic 
conditions which are managed by a range 
of specialists.1 35 Clinical guidelines are often 
disease‑specific and do not adequately support 
healthcare professionals who manage complex 
patients with multiple conditions.36 Patients 
may be overwhelmed by the amount of advice 
they receive on their conditions,37 and find it 
difficult to understand the association between 
AF, AF‑related stroke and their other conditions.
Crucially, AF is often diagnosed only after 
a person has had a serious complication 
such as an AF‑related stroke.38 This means 
patients are often trying to learn about 
the condition, and the complexities 
of its management, at a difficult time 
when they are simultaneously dealing 
with many other challenges. 
Low patient 
understanding of AF29
A survey conducted in 11 countries found 
that at least one in four patients felt 
unable to explain AF to another person. 
Only 57% of patients surveyed felt that 
the information provided by their doctor 
was easy to understand. Furthermore, 
more than one third of patients reported 
being worried or fearful about AF.
Box 2
Action focus 1: 
Supporting 
patient education
 ● Poor understanding of AF among newly diagnosed 
AF patients is common, and may affect their care 
and increase their risk of AF‑related stroke. 
 ● Healthcare professionals and patient organisations 
are best placed to educate patients. 
 ● Simple messages targeting different patient groups 
should be available across clinical settings.
Key messages
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Embedding shared 
decision-making across 
all settings of care
Healthcare professionals can play a key role 
in empowering patients and supporting 
them to take a more active role in their own 
care, through shared decision-making.3 39 
This can be achieved through:
 ● close collaboration between patient 
organisations and healthcare professionals 
in developing accurate information 
and resources that address patients’ needs 
 ● active healthcare professional engagement 
to help build patients’ skills, confidence 
and ultimate engagement in their care
 ● fostering development of tools to aid 
patient–clinician communication  
(see Box 3).
How can patient education be better supported?
We can do this by…
check
Developing simple, targeted 
messages for patients 
in a range of clinical settings
Accessible information about AF is urgently 
needed in a range of clinical settings. 
These materials should be available in local 
languages and be easily understandable 
to people with different levels of health 
literacy. Simple, targeted messages are needed 
to address the priorities of different groups, 
including patients, covering key elements of AF:
 ● AF as a condition – to encourage those 
at risk to get detected
 ● AF’s role as a risk factor for stroke
 ● Benefits and risks associated 
with anticoagulation to prevent 
AF‑related stroke
 ● The importance of continuing 
with the medication. 
AF stroke risk 
calculators40
AF stroke risk calculators were developed 
to help physicians calculate their patients’ 
risk of AF‑related stroke – but they also 
provide patients with a comprehensive 
assessment of their risk of stroke, coupled 
with critical information. The calculators run 
through a series of questions aligned with 
ESC guidelines to determine stroke risk. 
They provide patients with printable results 
and information on therapy options, which 
they can use to initiate discussion with their 
GP, cardiologist or neurologist. A number 
of AF stroke risk calculators are available, 
including one from the AF Association: 
http://www.preventaf‑strokecrisis.org/calculator 
Box 3
Action focus 1
Recommendation 1
 ● Build awareness and understanding of AF among patients and the wider  
population, through campaigns with simple, tailored messages implemented  
in a way that builds knowledge and supports shared decision‑making between  
patients and healthcare professionals.
check
1514
Action focus 2: 
Adapting clinical practice  
to enhance AF detection 
 ● AF is often detected only after the person has 
had an AF‑related stroke.
 ● Opportunistic screening for AF is recommended 
by the ESC, but many national guidelines do not 
include this recommendation.
 ● Opportunistic pulse rhythm checks are a simple 
way of detecting AF and should be introduced 
as standard practice across a range of care settings.
Key messages
What is the issue?
The timely detection and diagnosis of AF 
is critical in the prevention of AF-related 
stroke, but many patients are diagnosed 
only after they have had an AF-related 
stroke. There is a detection gap (in terms 
of the number of people who have AF but 
in whom it is undetected) of approximately 
10–45%, depending on the setting.19 41‑44
Detection of AF can be challenging as it 
often does not present with any obvious 
symptoms.46 In some patients, AF may have 
intermittent or even no symptoms, making 
detection difficult.  
The 2016 ESC guidelines recommend 
opportunistic pulse checks in people 
over 65 and an electrocardiogram (ECG) 
for confirmation of AF. These guidelines 
also recommend the systematic screening 
of high‑risk patients (who have had an 
ischaemic stroke or transient ischaemic attack 
(TIA)), as well as the consideration of systematic 
ECG screening in patients aged 75 and over, 
or those at high risk of stroke.1 
Regular checks for AF, however, are not 
common practice. A survey of 550 GPs 
in 11 European countries found that, in 10 of 
the countries, fewer than 20% of patients 
over 65 were checked for AF during routine 
GP appointments, despite this age group being 
at increased risk of AF (see Table 1).47
Table 1. Percentage of GPs 
who check patients for AF 
during routine appointments47
Country Percentage 
Belgium 12%
France 15%
Germany 13%
Italy 17%
Netherlands 5%
Norway 18%
Russia 42%
Spain 12%
Sweden 19%
Turkey 13%
United Kingdom 8%
In England, around 425,000 
people – or 30% of those 
with AF – are thought to have 
undiagnosed AF.42 
In Spain, 31% of people with AF 
who are over 60 years old have 
not had a diagnosis.45
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Why is this happening?
The evidence base on AF detection 
is evolving rapidly.
The case for opportunistic screening is well 
articulated in ESC guidelines, but the evidence 
on whether opportunistic and systematic 
screening for AF leads to reductions in 
AF‑related stroke is still evolving. This evidence 
gap has influenced decisions by policymakers 
against the introduction of AF screening 
programmes in the UK48 and Sweden.49 
Research is currently underway in both of these 
countries, however, to determine whether 
systematically screening patients for AF can 
reduce rates of AF‑related stroke.50 51   
Access to diagnostic services  
for AF is inconsistent.
Variable access to diagnostic services restricts 
the ability of healthcare professionals to identify 
people with AF. 
Even where opportunities for detection do 
exist, they may not be accessible by people 
who do not utilise health services due to 
cultural and linguistic barriers.53
Uptake of new screening tools 
has been limited.
Innovative screening tools that facilitate 
AF detection are a key aspect of the 
growing evidence base, but their adoption 
into routine medical practice has been 
limited. Handheld single‑lead ECG devices, 
for example, can provide a simplified, 
accurate and potentially cost‑effective way 
of screening for AF in high‑risk populations.54 55 
However, expert commentators have 
highlighted how financial constraints on 
healthcare systems may affect the uptake 
of this technology in medical practice.52
National guidelines often  
do not include recommendations 
for opportunistic screening  
of over-65s. 
Few national guidelines recommend 
opportunistic checks for AF. This is despite 
national cardiac society endorsement of 
the 2016 ESC guidelines in many countries,1 
and evidence that opportunistic screening leads 
to a statistically significant absolute increase 
in the proportion of people diagnosed with AF.56
Pulse rhythm checks are not integrated 
into routine care in many settings. 
Despite lobbying by patient organisations 
and professional societies in a number 
of countries – and the fact that pulse checks 
are a simple, quick and affordable tool 
to detect AF – decision‑makers have seldom 
chosen to include pulse rhythm checks as part 
of routine practice. 
Action focus 2 
We can do this by…
Introducing opportunistic pulse rhythm checks  
as standard practice 
Opportunistic pulse rhythm checks are 
appropriate for a range of care settings. 
Annual flu clinics in primary care using 
traditional59 or handheld ECGs,60 routine 
GP consultations61 62 and specialist clinics 
(such as for podiatry)63 have all been used 
to successfully detect AF. 
Routine hospital care can be adapted to 
include opportunistic checks for AF. Simple 
adaptations could be made to routine checks 
in the hospital, such as bedside checks on 
vital signs conducted by nurses or healthcare 
assistants. Training staff to record arrhythmia 
during these checks could provide a relatively 
low‑cost addition to normal care. 
For this practice to be effective, 
patient-focused pathways must be 
in place and health systems must 
be ready and resourced to manage higher 
numbers of AF patients. The development 
of programmes for opportunistic screening will 
likely lead to more cases of AF being identified. 
Robust referral pathways are essential 
to ensure patients are supported along 
the whole pathway, from detection to initiation 
of anticoagulation therapies, and access 
to therapies and ongoing care.65
Recommendation 2
 ● Introduce opportunistic detection of AF among high-risk groups  
through pulse rhythm checks across a range of clinical  
and non‑clinical settings. 
How can clinical practice be adapted  
to improve AF detection?
In Italy, GP guidelines 
recommend the opportunistic 
testing of patients for AF using 
pulse rhythm checks followed 
by an ECG confirmation.64
National guidelines in England57 
and France58 do not include 
opportunistic tests for AF. 
In Scotland, there is variation 
in access to 12‑lead ECGs; 
some National Health Service 
regions provide machines in all 
GP practices, while in others they are 
only available in hospitals. Waiting times 
of up to nine weeks for access to diagnostic 
services have been highlighted, which is 
problematic for patients who are unable 
to begin anticoagulation until their AF 
has been confirmed.52
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Improving efforts to 
detect AF in non-clinical 
and community settings 
Pulse rhythm checks in the community could be 
expanded to meet the needs of patient groups 
who may not access traditional health services. 
Innovative approaches are needed to identify 
‘missing’ groups and develop appropriate 
activities to engage them. Community‑based 
screening – led by pharmacists who are able to 
speak the communities’ languages, for example 
– has been shown to be successful (see Box 4).66
Robust referral pathways and access to ECG 
confirmation, therapies and ongoing care 
must be available, regardless of the setting 
in which the suspected AF is detected. Clear 
referral pathways ensure people with suspected 
AF identified in the community have timely 
access to an ECG for accurate confirmation.65 
 
Expanding training in the use of mobile 
ECG devices broadens access to accurate 
AF detection in the community. 
Professionals outside of healthcare could 
be trained to check ‘hard‑to‑reach’ groups 
for AF; for example, training fire and rescue 
personnel to use mobile ECG devices during 
Health and Safety Assessment visits with people 
over 65 has been shown to effectively target 
this high‑risk group.68 
Supporting stronger collaboration and communication 
between healthcare professionals 
Improving communication channels between healthcare professionals is crucial to the 
successful adaptation of clinical practice for AF detection. Poor coordination of care has been 
highlighted as a key concern for AF patients, with clinicians and other healthcare professionals 
not systematically sharing information.19 Centralised records of patient information can facilitate 
dialogue between different healthcare professionals, and should be investigated further. 
Building a shared understanding of diagnosis and clinical decision‑making among specialisms 
is also needed. This can be achieved through stronger interdisciplinary collaboration among 
healthcare professional societies, an area which is explored further in Action focus 4.
Improving screening for AF by optimising  
the use of new technology
Innovations in technology may offer 
opportunities to make AF screening 
more comprehensive and cost-effective. 
Increased availability of mobile, single‑lead 
ECGs may mitigate many of the issues 
associated with identifying AF, such as patient 
discomfort and long waiting times.69 
Technologies such as ECG patches 
can significantly improve the detection 
of AF. A study in the United States found 
that immediate monitoring using self‑applied 
continuous ECG monitoring patches at 
home for up to four weeks – compared with 
delaying ECG monitoring for four months 
– led to a significantly higher rate of AF 
diagnosis at four months, and greater 
initiation of anticoagulants in monitored 
individuals compared with those who 
were not monitored.70
Smartphone apps and smart watches 
can facilitate population screening and 
help uncover asymptomatic AF. A major study 
examining the feasibility of mass screening 
for AF has found promising results, although 
more evidence is needed to enable these 
technological solutions to be implemented 
on a mass scale (see Box 5). 
New technologies must be fully integrated 
into the care pathway in the same way 
that AF is detected in clinical or community 
settings, to ensure that people with 
suspected AF receive adequate follow-up 
care. In the case of smartphone apps, 
for example, key aspects of the pathway 
would include prescription of the app, 
effective monitoring and analysis of the data, 
referral for ECG testing if appropriate, 
and access to anticoagulation. 
Using a mobile app to 
detect AF in Belgium71 72
An app which has been registered 
in Europe as a medical diagnostic device 
is being trialled in Belgium. The app 
uses a smartphone camera to detect 
irregular pulse and has been used in 
two different ways:
 ● Prescribed by GPs who monitor 
the patient and coordinate follow‑up 
testing and care
 ● At a population level, through 
publishing an access code in a local 
newspaper. Within 48 hours, 12,328 
adults enrolled in the study, 136 of 
whom were identified with AF. Of these 
individuals, 40 were newly identified 
with AF and, among those, 21 went on 
to have their AF confirmed by their GP. 
Box 5
Action focus 2 
Detecting AF 
in community  
pharmacies66
The International Pharmacist for 
Anticoagulation Care Taskforce (iPACT) 
partnered with the Atrial Fibrillation 
Association (AF Association) to set up an 
initiative in 10 countries to actively involve 
community pharmacists in opportunistic 
screening for AF. Pharmacists took people’s 
pulse manually, and assessed symptoms 
and risk factors. People with an abnormal 
heart rate or rhythm were referred 
to a physician and, in some countries, 
pharmacists additionally confirmed 
the manual pulse check using a mobile 
single‑lead ECG. A total of 2,573 patients 
were included in the final analysis, with 
an irregular pulse detected in 212 patients 
(8.3%) and AF confirmed in 35 individuals, 
corresponding to a detection rate of 1.4%.
Box 4
In England, a pathway is being 
trialled which allows community 
pharmacists in London to refer 
people with an abnormal heart 
rhythm to a one‑stop AF clinic, after first 
testing them using a handheld device.67  
This has resulted in quick diagnosis of AF 
and access to appropriate anticoagulant 
therapy within two to three weeks, 
compared with the national average  
of 12 weeks. 
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What is the issue?
Many healthcare professionals lack 
adequate awareness and understanding 
of AF.33 A recent ESC educational needs 
assessment of European clinicians treating 
patients with AF highlighted a range of gaps, 
including:33
 ● uncertainty over how to deal with 
anticoagulant therapy, particularly 
in complex patients
 ● problems in using and interpreting 
risk assessment scores
 ● difficulties in AF detection associated 
with the complexity of symptoms.
These gaps lead to suboptimal management 
of patients with AF. Evidence suggests that 
clinicians often underestimate the risk of 
AF‑related stroke and overestimate the risk 
of bleeding, resulting in patients not receiving 
appropriate anticoagulation therapy.73 
Patients who do receive anticoagulation 
therapy are not always given adequate 
information on its benefits or the risks of 
discontinuing therapies, which likely contributes 
to low adherence.74 
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Action focus 3: 
Strengthening clinical  
and professional  
training in AF
 ●  Limited professional understanding of AF 
has a negative impact on patient care.
 ● Appropriate training materials are required 
to support the different needs of healthcare 
professionals along the whole patient pathway.
Key messages
Why is this happening?
Management of AF is complex 
owing to variable symptoms 
and the presence of other 
chronic conditions.
Symptoms vary not only from one patient 
to another, but also for the same individual 
at different time points.46 AF is more common 
in people with conditions such as diabetes and 
has a close association with heart failure,1 35 
which further complicates care. Primary care 
professionals, who may lack knowledge of AF, 
often deal with high numbers of patients with 
a wide range of conditions. Given their limited 
contact time with patients, professionals may, 
understandably, prioritise managing AF’s 
more immediate symptoms such as heart 
palpitations, dizziness, syncope (temporary loss 
of consciousness) and fatigue. 
Decisions over appropriate therapies 
to prevent AF-related stroke add further 
complexity. The decision to use any given oral 
anticoagulant therapy, for example, requires 
a careful balance of the potential benefits 
(stroke prevention) and risks (increased 
risk of bleeding) for each patient, as well as 
taking into account the patient’s preferences 
and values.34 75 76
Healthcare professionals’ 
educational needs are not 
well supported.
Professional educational needs relating to 
AF-related stroke prevention in non-cardiac 
settings are not well supported, despite 
many AF patients being cared for in primary 
care, emergency medicine and geriatrics. 
There is a lack of AF‑related stroke prevention 
guidelines for non‑cardiac specialists, despite 
notable exceptions such as for GPs in 
Ireland77 and Italy.64 Usually, the only available 
guidelines on the prevention of AF‑related 
stroke are for cardiologists, which may be too 
detailed and complex for non‑cardiac settings. 
This is compounded by the continuing historical 
misconception of AF as benign.78
It is not clear whether the educational 
tools that do exist are being optimally 
used. Tools currently available include online 
decision‑support tools,79 the GRASP‑AF tool 
developed to support GPs in the UK,80 and 
the ESC’s ‘pocket guidelines’ and CATCH ME 
mobile app.81 It is not clear, however, whether 
these tools are being used by healthcare 
professionals to support optimal patient care. 
Language barriers may inhibit the 
uptake of guideline recommendations. 
ESC guidelines are available in a limited number 
of languages,82 which may hinder their effective 
use by cardiologists across Europe, especially in 
areas where English is less widely understood.
There is a lack of guidance on referral 
pathways. The 2016 ESC guidelines, 
for example, do not include information on 
where and when AF patients should be referred, 
although they stress the need for a team 
approach to the management of AF patients.1 
Action focus 3 
Recommendation 3
 ● Increase knowledge and skills of healthcare professionals  
by developing tailored guidelines and tools, and ensuring existing tools  
are more widely used, where available. 
We can do this by…
Developing user-friendly guidelines and practical  
decision-making tools for healthcare professionals 
Accessible, tailored guidelines that 
include recommendations on referral 
pathways would support comprehensive 
implementation of ESC recommendations. 
GPs, for example, should be helped to define 
what care they should provide and for which 
patients, while also identifying patients with 
complex needs who should be referred 
to specialist care. Bespoke guidelines for 
pharmacists could help to carve a broader role 
for these professionals in both the detection 
of AF and anticoagulation medication 
management, taking advantage of their unique 
position in the health system. 
Existing guidelines, such as those for stroke, 
could be updated to include information 
on AF and anticoagulation therapy. The ESC, 
along with national cardiology organisations, 
should take a leading role in developing subsets 
of guidelines, and reaching out to national 
organisations for other disciplines to develop 
guidelines collaboratively. 
Decision-making tools would support 
the management of patients with AF. 
Educational tools to support the assessment 
of AF‑related stroke risk, and aid in the selection 
of the most appropriate anticoagulation therapy 
for each patient, could be particularly beneficial. 
The CHA2DS2‑VASc risk assessment tool has led 
to more accurate and appropriate assessment 
of risk and decisions on anticoagulation 
by cardiologists,83 and this needs to be 
incorporated into primary care IT systems 
to enable seamless implementation and 
support GPs in the decision‑making process.84 
Guidelines and decision-making tools must 
be made available in multiple languages 
to ensure access across Europe. The ESC 
could take the lead in working with national 
cardiology societies to ensure that at least 
the basic recommendations from the guidelines 
are translated into all European languages.  
Better use must also be made of existing 
tools. Stronger collaboration between national 
cardiology societies and other professional 
medical organisations, as well as with 
healthcare providers and patient organisations, 
could help to raise the profile of these tools and 
aid in their incorporation into clinical practice.85
How can clinical and professional training  
in AF be strengthened?
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Maximising peer-learning opportunities  
and training courses 
AF should be integrated into professional 
development programmes that meet 
healthcare professionals’ continuing 
professional development (CPD) 
responsibilities. Practical, short courses on AF 
care should be developed and tailored to the 
specific needs of different professionals and 
care settings, addressing common problems 
at various points of AF care. Training courses 
could also facilitate innovative changes 
to normal care, such as the adaptations to 
clinical practice described in Action focus 2. 
Collaboration among all stakeholders including 
healthcare professionals, patient organisations 
and policymakers is needed to develop 
and effectively roll‑out training courses. 
Publication in national clinical journals 
can also support professional learning. 
As such journals are usually written in local 
languages, they may be more accessible 
to clinicians than international scientific journals 
published in English. 
Web-based platforms offer further 
learning opportunities. For example, 
the Heart of AF programme, developed 
by the AF Association,87 provides healthcare 
professionals globally with resources to develop 
the skills and knowledge to better diagnose, 
treat and manage AF patients. 
Action focus 3 
In the UK, local cardiac 
and stroke networks that link 
patients, GPs, commissioners 
and providers for improved 
patient outcomes have been 
used to provide targeted training to 
non‑cardiac specialists.86 This has included 
training for primary care staff who run 
INR (international normalised ratio) clinics, 
where awareness of opportunistic pulse 
checks has been raised.  
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What is the issue?
AF-related stroke is severely 
under-represented in policy, 
performance and improvement efforts. 
There seems to be a lack of awareness 
among decision‑makers as to how AF links 
to wider policy goals such as the prevention 
of NCDs, healthy ageing and healthcare 
sustainability. Very few countries in Europe 
have a national plan targeting the prevention 
of AF‑related stroke.19 
This situation has allowed significant 
inequalities to endure unchallenged. 
There is, for example, variation across Europe 
in access to AF detection services: between 10% 
and 45% of people with AF remain undetected, 
depending on the setting.19 41 In addition, 
despite evidence on the cost‑effectiveness 
of using NOACs to prevent AF‑related 
stroke, access varies greatly from country 
to country.42‑44 For example, in many Eastern 
European countries, health service budget 
constraints mean NOACs are often limited to 
patients who have had a previous stroke or 
those with poor control on other therapies.88‑91 
This means many patients can access NOACS 
only if they cover the cost themselves, 
potentially limiting the use and duration 
of these therapies.  
Unlike other countries in 
Western Europe, Spanish 
guidelines do not align to 
the 2016 ESC guidelines and 
restrict the use of NOACs to a second‑line 
therapy in most cases.92 This is despite 
the fact that 40% of people with AF93 
– which amounts to over 300,00041 patients 
– are inadequately controlled using 
vitamin K antagonists (VKAs). 
In Italy, NOACs can be prescribed 
only if monitoring on other 
therapies is difficult, and only 
by authorised specialists.94 95 
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 ● AF‑related stroke is under‑represented in policy, 
which contributes to inequalities in access 
to AF detection and first‑line therapies to prevent 
AF‑related stroke. 
 ● Better articulation of the case for investment 
is needed, emphasising the cost of inaction.
 ● Population‑based registries and national health 
databases related to AF are necessary to increase 
the level of nationally and regionally relevant data. 
 ● Decision‑makers must be accountable for 
implementing changes to prevent AF‑related 
stroke; the Action Plan for Stroke in Europe 
2018–2030 presents an opportunity to achieve this.
 ● Strong collaboration between a range of disciplines 
is needed to advocate for change.
Action focus 4: 
Promoting awareness 
and accountability among 
decision‑makers for effective 
AF‑related stroke policies
Key messages
Why is this happening?
Awareness and understanding  
of AF is low.
Although AF is widespread, poor public 
awareness of the condition and its associated 
stroke risk continues to be a major hurdle,27 
and is reflected in low knowledge among 
policymakers and decision‑makers at all 
levels. In a series of interviews with different 
stakeholders from across Europe, respondents 
reported that policymakers’ understanding 
of AF is low, and that AF is often viewed 
as a medical issue rather than a public 
health issue.78 
The risk of AF-related stroke 
has not been well articulated.
The significant stroke risk resulting from AF 
has not been well articulated either at the 
public or policy level, which has led to AF being 
neglected in stroke policy. AF is not mentioned, 
for example, in the WHO’s Atlas of Heart Disease 
and Stroke, even though this resource aims 
to guide the development and implementation 
of appropriate policies on stroke, and despite 
AF fitting its three criteria for a major 
established risk factor for stroke.96
Implementation of national 
strategies at the regional 
or local level is variable.
Even where national AF and AF‑related 
stroke strategies exist, the differing priorities 
of sub‑national decision‑makers result in 
regional differences in their implementation. 
National collaboration among 
key AF stakeholders is inadequate.
A lack of collaboration between key 
stakeholders contributes to AF’s low visibility 
on the policy agenda. There is, for example, 
not usually a strong relationship between 
cardiology and neurology at the national level 
in most countries. The absence of collaboration 
may reduce the efficacy of key messages 
on AF and AF‑related stroke, and the impact 
of advocacy efforts. 
How can we promote awareness and greater     
accountability among decision‑makers?
We can do this by…
Better articulating the case for investment  
at national and sub-national levels
Policymakers and payers may be receptive 
to arguments focusing on the cost of 
inaction (e.g. the opportunity cost associated 
with not using NOACs) and return on 
investment. There is, for example, a growing 
body of ‘real‑world’ evidence on the benefits of 
anticoagulation for reducing stroke (see Box 6). 
There is also a growing evidence base on the 
cost‑effectiveness of NOACs compared with 
VKAs, despite their higher cost, which is at least 
in part due to the fact that, unlike VKAs, they do 
not require regular monitoring.9 11 12 In addition, 
there is increasing evidence on the case for 
investment in opportunistic screening, with 
research suggesting that screening of people 
aged 65 and over is likely to be cost‑effective.61
However, arguments aimed at the 
sub-national level must take into account 
the complexities and pressures affecting 
local decision-makers. The potential impact 
of economic evaluation will depend on whether 
cost‑effectiveness has become an explicit 
criterion to set health priorities at the local 
level.99 In Spain, this has occurred for some 
regions to guide recommendations on the 
use of new pharmaceuticals,99 while local‑level 
decisions in the UK are usually based on 
broader criteria, such as evidence of clinical 
benefit and budget impact.100 
These messages should be articulated via 
innovative methods. Educational events aimed 
at politicians, for example, have been shown to 
be an effective way of engaging with high‑level 
decision‑makers on AF (see Box 7).
Action focus 4
Recommendation 4
 ● Ensure policy leadership to drive equitable access to best practice.  
This can be achieved by building awareness and understanding of AF 
among policymakers and decision‑makers at all levels of the health system. 
In England, National Institute for 
Health and Care Excellence (NICE) 
guidelines recommend NOACs 
as an equal first‑line option to 
VKAs.90 Some local clinical commissioning 
groups, however, appear to interpret 
this as meaning NOACs are a second‑line 
option, with VKAs as first‑line.90 This may 
contribute to considerable variation 
in NOAC uptake between regions, ranging 
from approximately 4% to nearly 70% of all 
oral anticoagulant use in a 2015 survey.97      
In Spain, different policies 
are in place at the level 
of the autonomous regions, 
leading to wide variation 
in access to NOACs for the prevention 
of AF‑related stroke. In fact, in 2015, 
only 10 of the 18 autonomous regions 
applied national recommendations 
on access to NOACs, with the remaining 
eight applying additional access barriers.93 
UK data highlight 
a strong association 
between anticoagulation 
and stroke prevention98
Data from the UK found that changes 
in clinical practice between 2006 and 2016 
led to higher rates of anticoagulation 
and that this was associated with 
a decrease in the number of strokes. 
The study estimates that a 1% increase 
in the use of anticoagulant therapy was 
associated with a decrease of 0.8% in 
the number of AF‑related strokes per week. 
The authors of this study estimate that 
more than 4,000 AF‑related strokes were 
prevented in 2015–16 due to higher rates 
of anticoagulation compared with 2009. 
Box 6
Engaging and educating 
policymakers on AF 
The Arrhythmia Alliance and AF Association 
regularly host ‘Know Your Pulse’ events in 
parliaments in locations including England,101 
Scotland,102 Australia103 and at the European 
Parliament in Brussels,104 among others. 
During these events, politicians are offered 
a simple pulse rhythm check. Engaging 
with politicians – and identifying those with 
previously unknown AF – raises awareness 
while helping to influence policymakers 
and leading to action at the highest level.
Box 7
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Collecting relevant data to aid national  
and regional decision-making
Population-based AF registries and 
national health databases provide the 
data needed to understand inequalities 
and gaps in care, and missed opportunities 
to prevent strokes. These, however, do not 
exist in many countries. Currently, only 
Germany, Estonia and Latvia have invested 
in dedicated registries for AF, and only Denmark 
and Sweden have national patient registries 
that cover all conditions from which data 
on AF may be extracted.19 The value of these 
data can be seen in Denmark, for example, 
where the establishment of the Danish 
Stroke Registry has correlated with improved 
anticoagulation rates.105 
Regional-level data should be made available 
to local decision-makers. This would enable 
them to monitor performance and facilitate 
service development. 
Harnessing data to hardwire accountability  
at the policy level
Policymakers must be accountable for implementing changes to prevent AF-related stroke 
and ensuring that sufficient resources are committed to address inequalities in care. 
Accountability mechanisms should be developed to monitor, review and propose remedial 
action to ensure progress towards the agreed goals and targets.108 Impact assessments, 
for example, could contribute to the transparency of decision‑making, and allow the participation 
of stakeholders in public health, civil society groups and communities to increase accountability.109 
Dashboards charting the progress made in implementing agreed policies and actions could be 
a useful tool to ensure commitment and accountability.108 
Leveraging European and international  
work to gain momentum
The Action Plan for Stroke in Europe 
2018–2030110 presents a tangible opportunity 
to engage decision-makers and advance 
accountability around AF-related stroke 
prevention (see Box 8). At the national 
and regional level, the Action Plan can serve 
as a model for countries to develop their own 
AF policies and update their national NCD 
action plans. The World Heart Federation’s 
Roadmap for Nonvalvular Atrial Fibrillation 
is another such opportunity, as it focuses 
on topics aligned with WHO’s Global Action Plan 
targets for NCDs.111
Action focus 4
check
The Sentinel Stroke National 
Audit Programme (SSNAP) 
is the single source of stroke 
data in England, Wales and 
Northern Ireland. The SSNAP aids 
commissioners by providing them with 
region‑specific data every four months 
on a number of measures, such as 
the proportion of patients with AF 
on anticoagulation admitted to hospital 
for stroke. The programme also provides 
consistent benchmarking and regional 
breakdowns, allowing decision‑makers 
to compare their service performance 
with other regions.107 
The Danish Stroke Registry 
was established to monitor 
and improve the quality of 
care among all patients with 
acute stroke and TIA treated at Danish 
hospitals.105 Reporting is mandatory 
and an audit of the data is published 
annually and includes recommendations 
on improving quality of care.105 
Since the publication of data on the 
percentage of stroke patients with AF 
who are receiving anticoagulation therapy 
within 14 days of a stroke, anticoagulation 
rates have increased and the gap between 
anticoagulation rates in the capital 
and the rest of the country has closed.106 
Action Plan for Stroke 
in Europe 2018–2030110
The Action Plan for Stroke in Europe 
2018–2030 presents a tangible opportunity 
to engage decision‑makers and advance 
AF‑related stroke prevention.
It was developed jointly by the European 
Stroke Organisation (ESO) and SAFE in 2018. 
It aims to: reduce the absolute number of 
strokes in Europe by 10%; treat 90% or more 
of all patients with stroke in a stroke unit 
as the first level of care; have national 
plans for stroke encompassing the entire 
chain of care, from primary prevention 
to rehabilitation and life after stroke; 
and fully implement national strategies for 
multi‑sectoral public health interventions. 
The Action Plan aligns to global and 
European targets on NCDs and could 
be used to engage with the European 
Commission and/or the European 
Council Presidency to drive progress 
in AF‑related stroke.
Box 8
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Fostering strong cross-stakeholder  
collaboration 
Effective collaboration between 
healthcare professionals is crucial, such 
as that facilitated at the European level 
by the ESC Council on Stroke. The Council 
establishes links with ‘sister’ societies 
which aim to support and encourage 
collaboration and dialogue between 
disciplines. The Council helps contribute 
to the development and implementation 
of ESC Clinical Practice Guidelines, along with 
position papers and consensus documents. 
It also brings together its varied membership 
of healthcare professionals for interdisciplinary 
workshops and educational activities.112 
The ESO also supports multidisciplinary 
collaboration through its range 
of committees.113
This collaboration needs to be replicated 
with similar efforts at the national level, 
bringing clarity and consensus to political 
decision-making. Better collaboration 
between professional societies could help 
drive the changes outlined in the Action Plan 
for Stroke in Europe 2018–2030 by facilitating 
interdisciplinary dialogue and a stronger shared 
understanding of patient needs. 
Patient organisations’ potential to achieve 
recognition and policy commitment may 
be enhanced through multidisciplinary 
collaboration, such as with scientific 
professional and public health 
organisations. For example, the AF Association, 
Arrhythmia Alliance, AntiCoagulation Europe 
and SAFE have released a joint action plan 
on supporting the prevention of AF‑related 
stroke.114 In the UK, an All‑Party Parliamentary 
Group on AF has been established to provide 
a constructive forum for patient organisations 
to collaborate alongside healthcare 
professionals and members of parliament.101 
Action focus 4 
AF-related strokes are not only devastating for individuals 
and their families, they also place significant pressure on health 
services. Populations across Europe are ageing and, unless we take 
urgent action, the number of AF‑related strokes will rise significantly, 
impacting on the sustainability of our health systems.
We already have the tools we need to deliver effective care 
for patients with AF, but unacceptable inequalities exist 
in access, meaning huge opportunities to prevent AF-related 
stroke are being missed. The proportion of AF patients who are 
undiagnosed and therefore missing out on essential care for the 
prevention of AF‑related stroke varies greatly between countries. 
Similarly, barriers to accessing cost‑effective, first‑line therapies 
for the prevention of AF‑related stroke among already‑diagnosed 
patients is highly uneven between – and even within – countries. 
This White Paper has outlined four critical areas where change 
is urgently required. By working together, patient organisations, 
healthcare professionals and policymakers can drive these changes 
and ensure that all patients have access to the care they need. 
Conclusion
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